…the most practical advice at this time, for existing and potential customers, continues to be to understand the terms and conditions offered by each individual DTC genomics company with respect to their customers’ information–and to recognize that, in bankruptcy, genomic data may be transferred to a similar company without regard to those terms and conditions.
There’s also a tantalising promise of posts to come in the near future exploring the implications if impending regulatory changes in the DTC genomics area push testing companies firmly into the realm of clinical diagnostics.
Subscribe to Genetic Future.
Follow Daniel on Twitter.